Amendments to the Claims

1. (Previously presented) A fast-dissolving pharmaceutical composition in a solid dosage form, comprising micronized (R)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (hereinafter referred to as "AS-3201") having a mean particle size in a range of above 1 μm to less than about 20 μm in a ratio of about 0.5% by weight to about 25% by weight of the total weight of the pharmaceutical composition,

wherein when a dissolution percentage of AS-3201 from the composition is measured according to the Paddle method, 50% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

2. (Original) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is less than about 10 μm.

3. (Original) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is less than about 5 μm.

4. (Previously presented) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is in the range of above 1 μm - about 3 μm.

5. (Previously presented) A fast-dissolving pharmaceutical composition in a solid dosage form, which comprises micronized AS-3201 having a mean particle size in a range of above 1 μm to less than about 20 μm in a ratio of about 0.5% by weight - 5% by weight, a diluent in a ratio of about 51% by weight - about 93.8% by weight, a disintegrator in a ratio of about 5% by weight - about 35% by weight, a binder in a ratio of about 0.5% by weight -

about 5% by weight, and a lubricant in a ratio of about 0.2% by weight - about 4% by weight, relative to the total weight of the pharmaceutical composition,

wherein when a dissolution percentage of AS-3201 from the composition is measured according to the Paddle method, 50% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

6. (Original) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is less than about 10 μm.

7. (Original) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is less than about 5 μm.

8. (Previously presented) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is in the range of above 1 μm - about 3 μm.

9. (Original) The fast-dissolving pharmaceutical composition according to claim 5, which comprises a diluent in a ratio of about 59% by weight - about 88% by weight, a disintegrator in a ratio of about 10% by weight - about 30% by weight, a binder in a ratio of about 1% by weight - about 3% by weight, and a lubricant in a ratio of about 0.5% by weight - about 3% by weight.

10. (Original) The fast-dissolving pharmaceutical composition according to claim 6, which comprises a diluent in a ratio of about 59% by weight - about 88% by weight, a disintegrator in a ratio of about 10% by weight - about 30% by weight, a binder in a ratio of about 1% by weight - about 3% by weight, and a lubricant in a ratio of about 0.5% by weight - about 3% by weight.

11. (Original) The fast-dissolving pharmaceutical composition according to claim 7, which comprises a diluent in a ratio of about 59% by weight - about 88% by weight, a disintegrator in a ratio of about 10% by weight - about 30% by weight, a binder in a ratio of about 1% by weight - about 3% by weight, and a lubricant in a ratio of about 0.5% by weight - about 3% by weight.

12. (Original) The fast-dissolving pharmaceutical composition according to claim 8, which comprises a diluent in a ratio of about 59% by weight - about 88% by weight, a disintegrator in a ratio of about 10% by weight - about 30% by weight, a binder in a ratio of about 1% by weight - about 3% by weight, and a lubricant in a ratio of about 0.5% by weight - about 3% by weight.

13. (Previously presented) A fast-dissolving pharmaceutical composition in a solid dosage form, which comprises micronized AS-3201 having a mean particle size in a range of above 1 μm to less than about 20 μm in a ratio of more than 5% by weight and less than about 25% by weight, a diluent in a ratio of about 16% by weight - about 84.3% by weight, a disintegrator in a ratio of about 10% by weight - about 50% by weight, a binder in a ratio of about 0.5% by weight - about 5% by weight, and a lubricant in a ratio of about 0.2% by weight - about 4% by weight, relative to the total weight of the pharmaceutical composition,

wherein when a dissolution percentage of AS-3201 from the composition is measured according to the Paddle method, 50% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

14. (Original) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is less than about 10 μm.

15. (Original) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is less than about 5 μm.

16. (Previously presented) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is in the range of above 1μm - about 3μm.

17. (Original) The fast-dissolving pharmaceutical composition according to claim 13, which comprises a diluent in a ratio of about 29% by weight - about 73.5% by weight, a disintegrator in a ratio of about 20% by weight - about 40% by weight, a binder in a ratio of about 1% by weight - about 3% by weight, and a lubricant in a ratio of about 0.5% by weight - about 3% by weight.

18. (Original) The fast-dissolving pharmaceutical composition according to claim 14, which comprises a diluent in a ratio of about 29% by weight - about 73.5% by weight, a disintegrator in a ratio of about 20% by weight - about 40% by weight, a binder in a ratio of about 1% by weight - about 3% by weight, and a lubricant in a ratio of about 0.5% by weight - about 3% by weight.

19. (Original) The fast-dissolving pharmaceutical composition according to claim 15, which comprises a diluent in a ratio of about 29% by weight - about 73.5% by weight, a disintegrator in a ratio of about 20% by weight - about 40% by weight, a binder in a ratio of about 1% by weight - about 3% by weight, and a lubricant in a ratio of about 0.5% by weight - about 3% by weight.

20. (Original) The fast-dissolving pharmaceutical composition according to claim 16, which comprises a diluent in a ratio of about 29% by weight - about 73.5% by weight, a disintegrator in a ratio of about 20% by weight - about 40% by weight, a binder in a

ratio of about 1% by weight - about 3% by weight, and a lubricant in ratio of about 0.5% by weight - about 3% by weight.

21-62. (Cancelled)

63. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 1, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

64. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 2, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

65. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 3, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

66. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 4, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

67. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 5, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

68. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 6, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

69. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 7, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

70. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 8, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

71. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 9, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

72. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 10, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

73. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 11, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

74. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 12, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

75. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 13, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

76. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 14, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

77. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 15, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

78. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 16, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

79. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 17, wherein 80% or more of the AS-3201 in the tablet is dissolved within 15 minutes from the start of the method.

80. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 18, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

81. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 19, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

82. (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 20, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

83-88. (Cancelled)

89. (New) A fast-dissolving pharmaceutical composition in a solid dosage form, comprising micronized AS-3201 having a mean particle size of in a range of above 1 μm to less than about 20 μm in a ratio of about 0.5% by weight to about 25% by weight of the total weight of the pharmaceutical composition, and as a stabilizer at least one acidic substance having an acidity more potent than that of AS-3201,

wherein when a dissolution percentage of AS-3201 from the composition is measured according to the Paddle method, 50% or more of the AS-3201 in the composition is dissolved with 15 minutes from the start of the method.

90. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the acidic substance is a member selected from the group consisting of citric acid, tartaric acid, maleic acid and phosphoric acetate.

91. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.